Effectiveness of immunotherapy in aged leukemic mice

Area of Science:

• Immunology
• Cancer Research
• Gerontology

Background:

• Previous studies demonstrated successful immunotherapy using indomethacin and recombinant interleukin-2 (rIL-2) in young adult mice with hemopoietic tumors.
• This immunotherapy effectively stimulated natural killer (NK) cells and prolonged survival in young tumor-bearing mice.

Purpose of the Study:

• To evaluate the efficacy and age-universality of indomethacin and rIL-2 immunotherapy in aged, tumor-bearing mice.
• To determine if this immunotherapy regimen could enhance NK cell numbers and activity in older mice.

Main Methods:

• DBA/2 mice aged 10-16 months were induced with erythroleukemia.
• Mice received indomethacin, rIL-2, a combination, or no treatment (control).
• NK cell counts (ASGM-1+) and NK cell-mediated cytotoxicity (chromium release assay) were assessed.

Main Results:

• Tumor growth led to increased NK cell numbers, but neither indomethacin, rIL-2, nor their combination further increased NK cell counts in aged mice.
• The immunotherapy treatments did not enhance NK cell-mediated activity in tumor-bearing aged mice.
• Aged mice receiving immunotherapy did not show a significantly longer lifespan compared to untreated controls.

Conclusions:

• Aged mice exhibit resistance to the immunotherapy regimen that was effective in younger mice, suggesting an age-dependent effect.
• Immunotherapy efficacy may not be consistent across all age groups, highlighting the need for age-specific treatment considerations.
• This study underscores that successful treatments in one age demographic cannot be assumed to be effective in others.